SKYRIZI DIN 02546922
Status: Approved
Holder: ABBVIE CORPORATION
Health Canada record
| Active ingredient(s) | RISANKIZUMAB 90 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AC18 RIZANKIZUMAB |
|---|
| Original market date | |
|---|
| Current status date | 05-Apr-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RISANKIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02519283 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 150 MG | Marketed |
| 02519291 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 150 MG | Marketed |
| 02532093 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 360 MG | Marketed |
| 02532107 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 60 MG | Marketed |
| 02552507 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 180 MG | Marketed |
| 02487454 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 75 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33017 | 2024-04-05 | Supplement to a New Drug Submission (SNDS) | New presentation |
Request a quote for SKYRIZI
How to read a Canadian DIN record